Translatomics for chemotherapy, microprotein, and ALS
Recent Publications Harnessing the Power of Translatomics
Every week we provide a digest of a small number of recent interesting papers in the field of translatomics.
In this week’s Sunday papers,
- Yang et al. combine Ribo-seq and metabolomics to investigate how SLC15A3-mediated dipeptide metabolism helps lymphoma cells develop resistance to antimetabolite chemotherapy.
- Bonilauri and Yang use evidence from public Ribo-seq datasets to identify TGCB, a previously unannotated microprotein encoded by the lncRNA CHASERR, highlighting the potential of translation analysis to uncover hidden coding sequences.
- Lee et al. use ribosome profiling to investigate how an ALS-associated hnRNPA1 mutation affects translation, revealing altered ribosome occupancy and translation stalling alongside mitochondrial dysfunction.
SLC15A3-mediated dipeptide metabolism confers antimetabolite resistance in lymphoma via mTORC1 activation
The Journal of Clinical Investigation, 2026
Haojun Yang, Vincenzo Andrea Zingaro, Kevin Boardman, Ashish Noronha, Ekin Guney, Lingru Xue, Saishma Hoigebazar, Isabelle Liu, Sohit Miglani, Siyu Chen, Hieu Vu, Kwun Wah Wen, Hao G. Nguyen, Hani Goodarzi, Ralph J. DeBerardinis and Davide Ruggero
Antimetabolite chemotherapy, including 6-mercaptopurine (6-MP), targets nucleotide synthesis and is used to treat lymphoblastic leukaemia and B-cell lymphomas. However, cancer cells can develop resistance, and the metabolic adaptations that enable survival under nucleotide stress are not fully understood. This study investigated how MYC-driven lymphoma cells overcome nucleotide deficiency and whether these adaptations create new therapeutic vulnerabilities.
Using metabolomics, RNA sequencing (RNA-seq) and ribosome profiling (Ribo-seq), the researchers identified increased expression of the dipeptide transporter SLC15A3 in resistant lymphoma cells. The transcriptomic and translatomic analyses revealed increased expression and translation of genes associated with amino acid and oligopeptide transport. The team also found that resistant cells accumulated dipeptides containing essential amino acids.
Mechanistic experiments showed that SLC15A3 interacts with mTOR on lysosomes, promoting activation of mechanistic target of rapamycin complex 1 (mTORC1), a pathway that supports cell growth and survival. Reducing SLC15A3 expression diminished mTORC1 activity and restored sensitivity to 6-MP. Resistant lymphomas also showed increased sensitivity to the mTOR inhibitor rapamycin in experimental models. Analysis of human lymphoma biopsies provided additional evidence of increased SLC15A3 expression following antimetabolite treatment.
These findings reveal a link between dipeptide metabolism, translational regulation and chemotherapy resistance. They also suggest that targeting SLC15A3-associated signalling or mTORC1 could offer a strategy for treating resistant lymphoma.
Learn more about EIRNABio’s ribosome profiling services here.
Discovery of the TGCB microprotein translated from the lncRNA CHASERR
Biochimie, 2026
Bernardo Bonilauri and Xiaochun Yang
Long noncoding RNAs (lncRNAs) are generally studied for their roles in regulating gene expression, but some also contain small open reading frames (sORFs) that encode microproteins. CHASERR is a conserved lncRNA located near CHD2, a gene involved in neurodevelopment. Deletions affecting the CHASERR–CHD2 region have been associated with a severe early-onset neurodevelopmental disorder. This study investigated whether CHASERR encodes a previously unrecognised microprotein that might contribute to the biology of this locus.
The researchers identified a 41-amino-acid microprotein, named TGCB, encoded by an sORF within CHASERR. To investigate whether this sequence is actively translated, they integrated transcriptomic analyses, computational predictions and comparative evolutionary analyses with evidence from 47 publicly available ribosome profiling (Ribo-seq) datasets. Translation-associated ribosome footprints, including three-nucleotide periodicity and initiation-associated P-site enrichment, supported active translation of the sORF. The analysis also suggested evolutionary constraint on the encoded sequence.
Additional evidence included peptide-spectrum matches in public datasets and experiments examining TGCB localisation, which indicated that the microprotein can be found in both the nucleus and cytoplasm. Structural predictions suggested a compact alpha-helical region alongside intrinsically disordered segments.
The discovery challenges the assumption that CHASERR is exclusively noncoding and adds a potential functional element to a clinically relevant genomic region. Although the study does not establish that TGCB loss causes the associated disorder, it provides a candidate for further investigation and illustrates how ribosome profiling can help uncover hidden components of the proteome.
Learn more about EIRNABio’s ribosome profiling services here.
The hnRNPA1 D262V amyotrophic lateral sclerosis (ALS) mutation is linked to mitochondrial dysfunction
Genes & Development, 2026
Yeon J. Lee, Koning Shen, Andrew Dillin and Donald C. Rio.
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease associated with the loss of motor neurons. Several ALS-linked mutations affect RNA-binding proteins, which regulate RNA processing and other aspects of gene expression. The hnRNPA1 D262V mutation has been associated with altered RNA splicing, protein aggregation and cellular defects. This study investigated how this mutation affects RNA regulation, translation and mitochondrial function.
The researchers examined cells expressing mutant hnRNPA1 and used ribosome profiling to assess transcriptome-wide ribosome occupancy and translational dynamics. They observed altered ribosome occupancy across a subset of transcripts, including genes associated with synaptic organisation and GTPase functions. The data also indicated disrupted codon usage and widespread translation stalling, alongside suppression of mTOR/AKT signalling. These findings suggest that the mutation affects not only RNA processing but also the regulation and progression of protein synthesis.
The study additionally identified changes in RNA splicing and cellular phenotypes, including reduced proliferation and abnormal neuronal growth. Mitochondrial analyses revealed substantial dysfunction and fragmentation in cells carrying the mutation.
Together, the results broaden understanding of how a disease-associated RNA-binding protein mutation can affect multiple cellular processes. The ribosome-profiling findings are particularly relevant to translational biology because they show how a mutation in an RNA-processing factor can coincide with altered ribosome behaviour across the transcriptome. However, the findings do not establish that translation defects alone cause mitochondrial dysfunction or ALS pathology.
Learn more about EIRNABio’s ribosome profiling services here.